Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Date:9/4/2007

amsulosin 0.4 mg/day (n=1519).

ABOUT AVODART

AVODART, the first and only dual 5ARI for the treatment of enlarged prostate, inhibits both the type I and type II isoenzymes responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is the primary male hormone responsible for the enlargement of the prostate. AVODART provides the power to suppress DHT by 93 percent at 2 years. Over time, AVODART reduces prostate volume, improves symptoms and arrests the enlarged prostate disease process.

AVODART is indicated for the treatment of symptomatic enlarged prostate in men with an enlarged prostate to improve urinary symptoms, reduce the risk of AUR, and reduce the risk of enlarged prostate-related surgery. While some men have fewer problems and symptoms after three months of treatment with AVODART, a treatment period of at least six months is usually necessary to see if AVODART will improve symptoms.

Only a doctor can tell if symptoms are from an enlarged prostate and not a more serious condition such as prostate cancer. Men should see their doctors for regular exams. Women and children should not take AVODART. Women who are, or could become pregnant should not handle AVODART due to the potential risk of a specific birth defect. Men treated with AVODART should not donate blood until at least six months after their final dose.

Caution should be used in patients with liver disease. Possible side effects include sexual side effects and breast tenderness and/or swelling. These side effects occur infrequently.

For full prescribing information, see http://www.avodart.com.

About Enlarged Prostate

Enlarged prostate is a prevalent and progressive condition that affects 50 percent of men over 50 years of age and over 90 percent of men older than age 80. An enlarged prostate causes changes in urinary habits because of its location around the urethra. Over time, the p
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
(Date:5/22/2015)... May 22, 2015 Today, Rhodes Pharmaceuticals ... system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity ... Summer 2015. The announcement comes ... from the U.S. Food and Drug Administration (FDA). ... formulation of methylphenidate capsule with an onset of ...
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "North ... Replacement, Digit Replacement, Elbow Replacement, Hip Replacement, ... 2019" report to their offering. ,     ... replacement was valued at $4,470.9 million in ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... April 15 Tomorrow Congress will,hold hearings on whether the ... The answer is "no." The biggest culprit is the,CDC. ... U.S.,hospitals each year. The truth is several times that ... the fastest growing infections is "Mersa" or MRSA, which ...
... has,announced that HuMax-EGFr (zalutumumab) inhibits epidermal growth ... receptor (EGFr),molecules into a very compact, inactive ... to its role in signaling, and binding ... cancer cell growth., Genmab A/S (OMX: ...
Cached Medicine Technology:April 16th Congressional Hearing on Hospital Infections 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 3
(Date:5/25/2015)... (PRWEB) May 26, 2015 The ... Hooker as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in dentistry. NAPW is ... boasting more than 700,000 members and over 200 operating ... into this exceptional group of professional women,” said NAPW ...
(Date:5/25/2015)... The National Association of Professional ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in biomedical engineering. NAPW is the ... more than 700,000 members and over 200 operating Local ... exceptional group of professional women," said NAPW President Star ...
(Date:5/25/2015)... 25, 2015 World Patent Marketing, a ... the Big Little Party Table, a party invention that ... that will suit their party needs. , "Worldwide indoor ... billion this past year. Party Supply Rentals alone ... J. Cooper, CEO and Creative Director of World ...
(Date:5/25/2015)... 24Hr HomeCare is proud to announce ... & COO, and Ryan Iwamoto, Co-Founder & CMO, are ... Year® 2015 Awards in Greater Los Angeles. The award ... in innovation, financial performance, and a personal commitment to ... of the ongoing success of our organization,” said Co-Founder ...
(Date:5/25/2015)... 25, 2015 A recent report for ... persons have died as a direct result of an opiate ... a 33% rise in overdose deaths attributed to prescription opiate ... issue doesn’t care about geography. This issue doesn’t care about ... care about class.” As the state of Mass. reels from ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2
... , ... organization dedicated to ending malaria deaths and empowering communities, ONE bracelet at a time (Buy ... contracting Malaria, and encourages others to join in the fight against this deadly disease. Malaria ... Malaria kills a child every 30 seconds. , ...
... shorter length of leukocyte telomeres chromosome markers of biological ... and death from cancer, according to a study in the ... a type of blood cell. Telomeres are a structure ... and stability of the chromosome. Genetic factors and environmental stressors ...
... COLUMBUS, Ohio Scientists have designed a nanoparticle that appears ... effects. In lab experiments, the researchers have found that ... enough into a cell to allow genetic material to be ... is between 2 and 10 times more effective than ...
... July 6, 2010 (BRONX, NY) Researchers have linked ... motivation, reward and addiction cravings, according to a study published ... . Lucy Brown, Ph.D., clinical professor in the Saul R. ... College of Medicine of Yeshiva University, is the corresponding author ...
... ... additional foot problems such as bunions, hammertoes, arthritis and calluses, and improve a person’s ... Surgery. , ... IL (Vocus) July 6, 2010 -- Treatment and prevention of adult flatfoot can reduce ...
... prevent potentially dangerous blood clots in recovering surgical patients ... illness, doctors have found in a multi-institutional study. ... strictly confined to 24-hour bed rest, a month of ... chances of blood clots while only slightly increasing the ...
Cached Medicine News:Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 3Health News:Length of biological marker associated with risk of cancer 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Study links romantic rejection with reward and addiction centers in the brain 2Health News:Don't Ignore Flat Feet,Study links this condition to painful foot maladies 2Health News:Extended use of anti-clotting drug helps some bedridden patients 2Health News:Extended use of anti-clotting drug helps some bedridden patients 3
... For the quantitative determination ... human serum. Progesterone ... the principle of competitive ... the test specimen and ...
... Insulin is the only physiologic hormone ... response to a number of stimuli, including ... into the hepatic portal circulation [1,2]. Although ... by the liver, the remainder enters the ...
ELISA for the detection of 17a OH Progesterone....
... a steroid produced in the adrenal gland ... role except as a precursor molecule. In ... to cortisol by the sequential actions of ... glands and ovaries, 17alpha-OH-P can be converted ...
Medicine Products: